<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146677">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191008</url>
  </required_header>
  <id_info>
    <org_study_id>A6641056</org_study_id>
    <nct_id>NCT01191008</nct_id>
  </id_info>
  <brief_title>Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension</brief_title>
  <official_title>Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Investigation is to evaluate the safety and efficacy of long-term
      treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse
      drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey
      period, and whether an additional treatment outcome investigation and/or a post-marketing
      clinical study is required in the future will be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the first Xalacom® should be registered
      consecutively until the number of subjects reaches target number in order to extract
      patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse drug reactions.</measure>
    <time_frame>Max 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse drug reaction not expected from the LPD (unknown adverse drug reaction).</measure>
    <time_frame>Max 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy rate for the patients of glaucoma or ocular hypertension.</measure>
    <time_frame>Max 104 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">661</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Latan-timolol maleate fixed comb ophthalmic solution</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost-timolol maleate fixed combination ophthalmic solution</intervention_name>
    <description>Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. &quot;One drop should be applied to the affected eye(s) once daily&quot;.</description>
    <arm_group_label>Latan-timolol maleate fixed comb ophthalmic solution</arm_group_label>
    <other_name>Xalacom</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients whom an investigator involving A6641056 prescribes the Xalacom® Combination
        Eye Drops.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients need to be administered Xalacom® in order to be enrolled in the
             surveillance.

        Exclusion Criteria:

          -  Patients not administered Xalacom®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6641056&amp;StudyName=Long%20Term%20Use%20Of%20Xalacom%20In%20Patients%20Glaucoma%20Or%20Ocular%20Hypertension</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 30, 2015</lastchanged_date>
  <firstreceived_date>August 26, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xalacom Regulatory post marketing commitment plan safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
